Curated News
By: NewsRamp Editorial Staff
September 03, 2025
Kairos Pharma CEO to Present at Prestigious Investment Conference
TLDR
- Kairos Pharma's CEO presentation at H.C. Wainwright conference offers investors early insight into ENV105's potential to revolutionize cancer treatment resistance.
- Kairos Pharma's ENV105 antibody targets CD105 protein to reverse drug resistance in cancer, currently in Phase 2 trials for prostate and Phase 1 for lung cancer.
- Kairos Pharma's innovative cancer therapy ENV105 aims to restore treatment effectiveness, potentially improving survival and quality of life for cancer patients worldwide.
- Kairos Pharma leverages structural biology to combat cancer drug resistance with ENV105, presenting at the H.C. Wainwright conference in September 2025.
Impact - Why it Matters
This development matters because cancer drug resistance remains one of the most significant challenges in oncology treatment, often leading to treatment failure and disease progression. Kairos Pharma's innovative approach targeting CD105 could potentially revolutionize cancer therapy by making existing treatments more effective and addressing the critical problem of resistance. For patients, this represents hope for more durable responses to cancer treatments. For investors and the medical community, it signals important progress in the ongoing battle against cancer and highlights the potential for breakthrough therapies that could transform patient outcomes across multiple cancer types.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company based in Los Angeles, California, announced that its CEO and Chairman Dr. John Yu will present a corporate overview at the prestigious H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at New York's Lotte New York Palace Hotel. This presentation offers investors and the financial community crucial insights into the company's innovative cancer therapeutics pipeline and strategic direction.
The company's groundbreaking work focuses on overcoming drug resistance and immune suppression in cancer through structural biology approaches. Their lead candidate, ENV105, represents a significant advancement in oncology—an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. When CD105 levels elevate in response to standard therapy, it leads to treatment resistance and disease relapse. ENV105 aims to reverse this resistance mechanism and restore the effectiveness of standard cancer therapies across multiple cancer types.
Currently, ENV105 is advancing through clinical trials with a Phase 2 study for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing substantial unmet medical needs in oncology. The company's participation in the H.C. Wainwright conference, facilitated through the InvestorBrandNetwork's Dynamic Brand Portfolio and enhanced press release distribution capabilities, provides vital exposure to potential investors and partners interested in cutting-edge cancer research and investment opportunities in the biopharmaceutical sector.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma CEO to Present at Prestigious Investment Conference
